AWA
REGN icon

Arkadios Wealth Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Arkadios Wealth Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.06M Buy
1,700
+400
+31% +$272K 0.02% 779
2026
Q1 		$1M Buy
1,300
+900
+225% +$689K 0.02% 782
2025
Q4 		$309K Buy
+400
New +$272K 0.01% 1238

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Arkadios Wealth Advisors's REGN Position: Q2 2026 in Review

Arkadios Wealth Advisors increased its Regeneron Pharmaceuticals (REGN) stake by 17% in Q2 2026, buying an estimated $524K and bringing the position to 5,205 shares worth $3.25M. The position accounts for 0.05% of the portfolio, ranked #379.

Arkadios Wealth Advisors first reported a position in REGN in Q1 2020 and has held it in 14 quarters since. The position peaked at $3.43M in Q1 2026. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Arkadios Wealth Advisors held 5,205 shares of Regeneron Pharmaceuticals worth $3.25M as of Q2 2026.
  • Arkadios Wealth Advisors bought 770 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $524K.
  • Regeneron Pharmaceuticals made up 0.05% of Arkadios Wealth Advisors's portfolio in Q2 2026, its #379 holding.
  • Arkadios Wealth Advisors first reported a position in Regeneron Pharmaceuticals in Q1 2020 and has held it in 14 quarters since.
  • Arkadios Wealth Advisors's Regeneron Pharmaceuticals position peaked at $3.43M in Q1 2026.
  • 1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Arkadios Wealth Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.